Ubs Group Ag Synlogic, Inc. Transaction History

Ubs Group Ag

18 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 12, 2023	BUY	$0.56 - $1.07 $4,928 - $9,417	8,801 New	8,801 $5,000
Q2 2022 Aug 10, 2022	SELL	$0.89 - $2.47 $31,278 - $86,805	-35,144 Closed	0 $0
Q1 2022 May 16, 2022	BUY	$1.63 - $2.55 $57,284 - $89,617	35,144 New	35,144 $84,000
Q4 2021 Feb 14, 2022	SELL	$2.27 - $3.0 $8,871 - $11,724	-3,908 Closed	0 $0
Q3 2021 Nov 15, 2021	SELL	$2.45 - $4.1 $2,151 - $3,599	-878 Reduced 18.35%	3,908 $12,000
Q2 2021 Aug 13, 2021	BUY	$3.0 - $4.39 $14,358 - $21,010	4,786 New	4,786 $19,000
Q4 2020 Feb 11, 2021	SELL	$1.85 - $2.54 $5,775 - $7,929	-3,122 Closed	0 $0
Q3 2020 Nov 12, 2020	BUY	$1.85 - $2.57 $5,775 - $8,023	3,122 New	3,122 $6,000
Q2 2020 Jul 31, 2020	SELL	$1.59 - $2.51 $17,868 - $28,207	-11,238 Closed	0 $0
Q1 2020 May 01, 2020	SELL	$1.39 - $3.19 $14,720 - $33,782	-10,590 Reduced 48.52%	11,238 $19,000
Q4 2019 Feb 14, 2020	BUY	$1.96 - $2.81 $17,189 - $24,643	8,770 Added 67.16%	21,828 $56,000
Q3 2019 Nov 14, 2019	SELL	$2.12 - $9.37 $11,403 - $50,401	-5,379 Reduced 29.18%	13,058 $30,000
Q2 2019 Aug 14, 2019	BUY	$6.27 - $9.48 $42,554 - $64,340	6,787 Added 58.26%	18,437 $168,000
Q1 2019 May 14, 2019	SELL	$7.01 - $10.24 $1,759 - $2,570	-251 Reduced 2.11%	11,650 $88,000
Q4 2018 Feb 14, 2019	BUY	$5.95 - $14.49 $41,215 - $100,372	6,927 Added 139.26%	11,901 $83,000
Q3 2018 Nov 14, 2018	BUY	$7.51 - $14.21 $23,806 - $45,045	3,170 Added 175.72%	4,974 $71,000
Q2 2018 Aug 14, 2018	BUY	$9.01 - $13.33 $16,172 - $23,927	1,795 Added 19944.44%	1,804 $18,000
Q1 2018 May 15, 2018	BUY	$9.38 - $12.12 $84 - $109	9 New	9 $0

25.5K

Ticker SYBX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 70,229,600
Market Cap $103M
Description
Synlogic, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of synthetic biotic medicines to treat metabolic and immunological diseases in the United States. Its therapeutic programs include SYNB1618 and SYNB1934 that are orally administered, non-systemically absorbed drug candidates, which are in Phase I...

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

Stay updated on Ubs Group Ag with notifications on news.